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INTRODUCTION
Catechol-O-methyl transferase (COMT) O-methylates
compounds with a catechol moiety in the presence of a Mg2+ ion
using S-adenosyl-L-methionine (AdoMet, SAM) as a methyl
donor (1, 2). The COMT gene (COMT) codes for two isoforms
of COMT, soluble (S-COMT) and membrane-bound (MB-
COMT) proteins (3, 4). The latter protein is otherwise identical
to S-COMT but it incorporates 50 additional hydrophobic amino
acids (in humans) that form the membrane anchor (3, 5). COMT
contains six exons, the first two of which are non-coding. In
exon 3, there are two AUG start codons for two promoters that
control expression of the two COMT transcripts (6). The distal
P2 promoter regulates the synthesis of a 1.5-kb transcript in
humans. Based on the leaky scanning mechanism of translation
initiation, this longer transcript can code for both S-COMT and
MB-COMT proteins (6-8). The P1 promoter almost completely
overlaps exon 3 and falls between the S-COMT and MB-COMT
ATG start codons, partially overlapping the MB-COMT coding
sequence. Therefore, the shorter mRNA transcript (1.3 kb in
humans) regulated by P1 only codes for the S-COMT protein.
S-COMT and MB-COMT share the same kinetic mechanism;
however, the kinetic parameters are somewhat different. S-
COMT has a high Km value for dopamine but very high
enzymatic capacity (Vmax up to nearly 15,000 pmol/min per mg
protein in liver) (1, 9). MB-COMT, on the other hand, has low Km
value and low capacity (only 2 – 40 pmol/min per mg protein).
Furthermore, MB-COMT has a higher affinity for
catecholamines than S-COMT (10). Therefore, it has been
postulated that S-COMT has an important role in O-methylation
when substrate levels are high (e.g. food-derived catechol
compounds in gut), whereas MB-COMT gains more importance
at low substrate levels (e.g. brain catecholamine
neurotransmitters) (11-13). In addition, the two enzyme isoforms
differ by the regioselectivity of O-methylation: MB-COMT
strictly prefers 3-O-methylation (meta/para ratios between 22 and
88, depending on substrate), whereas S-COMT allows slightly
more 4-O-methylation (meta/para ratio between 4 and 15) (14).
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Catechol-O-methyltransferase (COMT) has two isoforms: soluble (S-COMT), which resides in the cytoplasm, and
membrane-bound (MB-COMT), anchored to intracellular membranes. COMT is involved in the O-methylation of L-
DOPA, dopamine and other catechols. The exact role of MB-COMT is still mostly unclear. We wanted to create a novel
genetically modified mouse model that specifically lacks MB-COMT activity and to study their behavioral phenotype.
MB-COMT knock-in mutant mice were generated by introducing two point mutations in exon 2 of the Comt gene
(ATGCTG->GAGCTC disabling the function of the P2 promoter and allowing only the P1-regulated S-COMT
transcription. The first mutation changes methionine to glutamic acid whereas the second one does not affect coding.
The expression of the two COMT isoforms, total COMT activity in several areas of the brain and peripheral tissues and
extracellular dopamine concentrations after L-DOPA (10 mg/kg) and carbidopa (30 mg/kg) subcutaneous administration
were assessed. A battery of behavioral tests was performed to compare MB-COMT deficient mice and their wild type
littermates of both sexes. MB-COMT deficient mice were seemingly normal, bred usually and had unaltered COMT
activity in the brain and periphery despite a complete lack of the MB-COMT protein. MB-COMT deficient male mice
showed higher extracellular dopamine levels than their wild-type littermates in the striatum, but not in the mPFC. In
addition, the MB-COMT deficient male mice exhibited a distinct endophenotype characterized by schizophrenia-related
behaviors like aggressive behavior and reduced prepulse inhibition. They also had prolonged immobility in the tail
suspension test. Both sexes were sensitized to acute pain and had normal motor activity but disturbed short-term
memory. Hence the behavioral phenotype was not limited to schizophrenia-related endophenotype and some behavioral
findings were not sex-dependent. Our findings indicate that MB-COMT is critical for behavior, and its function in
COMT-dependent brain areas cannot be entirely substituted by the remaining S-COMT.
K e y  w o r d s : catechol-O-methyl transferase, membrane-bound catechol-O-methyl transferase, behavior, schizophrenia, sexual
dimorphism, pain sensitivity
COMT is an intracellular enzyme, and in the brain it has been
localized to glial cells and short postsynaptic neurons (13, 15,
16). Subcellularly, S-COMT has been found in the cytosol as well
as in the nucleus while MB-COMT is associated with
intracellular membranes but - notably - not with the cell
membrane (16-18). Recently, however, these unanimous views
have been disputed by one study giving some evidence for an
extracellular position of COMT and for its localization in
presynaptic catecholaminergic neurons (19). Nevertheless, due to
the requirements of the chemical environment (pH,
concentrations of Mg2+, Ca2+ and SAM), it is unlikely that COMT
enzyme reactions could effectively happen outside cells (13).
COMT is widely distributed throughout the body, with the
highest protein and activity levels found in the liver, kidneys and
gut (2, 20). COMT gene expression is fairly uniformly
distributed in the body. The highest levels are found in the
adrenal gland followed by liver, esophageal mucosa, spinal cord
and peripheral nerves. Notably, COMT gene expression levels
are at medium level in the brain with only slight fluctuation
between the areas (21).
Until recently, it has been difficult to gain reliable information
on the tissue distribution of enzyme isoforms because isoform-
selective antibodies are not available. Using subcellular
fractionation, Lundstrom and coworkers (22) suggested that S-
COMT is the predominant isoform in the periphery, whereas MB-
COMT may dominate in the human but not rat brain. Analysis of
COMT distributions in mutant mice selectively lacking S-COMT
(17, 23) confirmed the importance of MB-COMT in brain tissue
and the dominance of S-COMT in peripheral tissues (17).
Nevertheless, the distribution of COMT isomorphs seems to be
species-dependent, as Lundstrom et al. (22) and Ellingson et al.
(24) suggested that S-COMT is dominant at least in certain areas
of the rat brain (cerebellum, cortex). An important role for COMT
in the brain is supported by the fact that the well-known COMT
Val/Met polymorphism has been associated with different
psychiatric and neurological conditions, for example with
depression (25), schizophrenia (26), pain sensitivity (27), and
memory impairment (28). There is an optimum level of COMT
activity for the maintenance of optimum catecholaminergic tone,
and both low COMT (associated with high catecholaminergic
tone) and high COMT activity (low catecholaminergic tone) may
cause problems (29, 30).
In the present study, we generated a novel genetically
modified mouse strain that is selectively deficient in MB-COMT
protein. Since the association of COMT polymorphism with
schizophrenia in general is still a hot topic (31-33), we were
interested in behavioral endophenotypes that have been proposed
to model manifestations of schizophrenia, such as aggressive
behavior (34), prepulse inhibition (35) and memory impairment
(36), in mice. To get a more general view of their behavior, also
general motor activity, pain sensitivity and depression
endophenotype were assessed. We demonstrate how the genetic
modification affects the levels of MB-COMT protein expression
as well as COMT activity in the mouse brain and peripheral
tissues. We also show how MB-COMT deficiency impacts
extracellular dopamine and the behavioral phenotype of mice.
MATERIALS AND METHODS
Generation of MB-COMT deficient mouse strain
1. Targeting construct
The MB-COMT-deficient strain was constructed by two
point mutations (ATGCTG to GAGCTC) of P2 promoter in exon
2 of the Comt gene (Fig. 1). The first mutation induces a change
of methionine to glutamic acid, the second mutation does not
affect coding (leucine remains leucine). Briefly, a BAC clone
containing exons 2 to 4 and partial exon 5 of Comt gene was
subcloned into a minimal vector, pACYC177. To generate point
mutations in exon 2, DNA fragment containing exon 2, introns 1
and 2 amplified by PCR was inserted into pGEM-4Z vector
digested with EcoRI and SmaI. The point mutations in exon 2
were introduced into the pGEM-4Z clone by site directed
mutagenesis using QuikChange Site-Directed Mutagenesis kit
(Stratagene, CA, USA). A neo-resistant gene flanked with two
loxP sites was introduced into intron 2 with a loxP-PGK-Neo-
loxP cassette (Gene Bridges, Heidelberg, Germany). Finally, a
3012-bp DNA fragment containing exon 2 with point mutations
and Neo cassette was excised from pGEM-4Z with SmaI and
XbaI and replaced wild type exon 2 region in pACYC177
backbone by Red/ET recombination.
2. Gene targeting and screening of colonies in embryonic
stem cells
G4 embryonic stem cells (ES, derived from mouse
129S6/C57BL/6Ncr) were cultured on neomycin-resistant
primary embryonic fibroblast feeder layers, and 106 cells were
electroporated with 30 µg of linearized targeting construct. After
electroporation, the cells were plated on 100-mm culture dishes
and exposed to G418 (300 µg/ml; Sigma). Colonies (288) were
picked after 7 – 9 days selection, and grown on 96-well plates.
In order to delete Neo cassette in the targeted ES cells, the cells
were re-electroporated with the plasmid pCAGGS-Cre. After
electroporation, the cells were plated on 100-mm culture dishes
and colonies were picked after 3 – 5 days growth, and grown on
96-well plates. In order to detect targeted ES clones with Neo
deletion, DNAs isolated from these colonies were screened by
PCR with several different primer pairs. More than 20 correct
clones were found from 96 clones. The right clones were further
confirmed by sequencing.
3. Producing a MB-COMT deficient mouse colony
Positive ES clones were used for blastocyst injection.
Chimeric males were mated with C57BL/6J females, and DNA
from tissue samples taken from ear lobes of F1 pups was typed
by PCR (see below). F1 heterozygous mice were mated, and F2
mice of all three genotypes were obtained. Heterozygous and
homozygous MB-COMT deficient mice are healthy and viable,
and they breed normally. This could be expected because the
Comt gene disrupted knock-out mice (37, 38) as well as S-COMT
deficient mutant mice (23, 39) are also seemingly normal.
Homozygous male and female mice of the MB-COMT strain
as well as their wild-type (WT) littermates were used for the
animal experiments. The mice were bred at the Laboratory Animal
Centre of University of Helsinki, Finland, and the sixth to seventh
generations of the heterozygous mating pairs were used for the
experiments. The mice were regularly backcrossed to C57BL/6J
females and less than 2% of 129S6 background was left in the 7th
generation. The animals were weaned, sexed and earmarked at the
age of three weeks. After weaning, they were group housed in
clear polycarbonate individually ventilated filter-top cages under
12:12 light cycle at an ambient temperature of 22°C with drinking
water and mouse chow available ad libitum.
The genotype of WT and MB-COMT deficient (either
heterozygous or homozygous) mice was determined from ear
biopsies obtained during ear marking using a PCR method. The
PCR mix consisted of 3'HAUF2 (5'-
GAAGTGGGTATGGCAGCGCTTATA-3') and 5'HADR2 (5'-
AACACACATTCCTCTCATGCTCCT-3') primers (Oligomer,
Helsinki, Finland) as well as FailSafe system premix B and PCR
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enzyme (Epicentre, Madison, WI, USA). The amplified
fragments were visualized with SYBR Green (Qiagen, Venlo,
The Netherlands) staining under UV-light after electrophoresis
in 1.7% agarose gel. An example of the genotyping results is
shown in Fig. 1B and the corresponding western blots in Fig.
1C. Animals were used for experiments when they were two to
three months old. The phase of the estrus cycle was not
determined.
Animal experiments were conducted according to the 3R
principles of the EU directive governing the care and use of
experimental animals (2010/63/EU), and following local laws
and regulations (Finnish Act on the Protection of Animals Used
for Scientific or Educational Purposes (497/2013), Government
Decree on the Protection of Animals Used for Scientific or
Educational Purposes (564/2013)). The protocols were
authorized by the national Animal Experiment Board of Finland.
Total COMT activity assay
Brain and peripheral tissues for total COMT activity assay
were collected from homozygous MB-COMT deficient and
wild-type mice of both sexes. The tissues were frozen on dry ice
and stored at –80°C before analysis. Detailed method of the
COMT activity assay is given elsewhere (23). Activity data is
given as picomoles of vanillic acid (and isovanillic acid for
meta/para calculation) formed per minute per milligram of
tissue. Besides a regular COMT assay with a high substrate
concentration (400 µM of dihydroxy benzoic acid, DHBAc),
liver COMT activities were measured also with graded
concentrations of DHBAc (3, 30 and 300 µM) and enzyme
kinetics (Km and Vmax) were calculated with GraphPad Prism
5.0. (San Diego, CA, USA). Hippocampal COMT activities
were measured also with two lower DHBAc concentrations (30
and 300 µM).
Western blotting
For Western immunoblotting (WB), the tissue samples were
collected from at least two male and two female mice and rinsed
in physiological saline solution. Immediately after dissection,
the tissues were placed in ice-cold centrifuge tubes on dry ice to
minimize decomposition. All the tissue samples were frozen and
stored in –80°C until analyzed. Tissues (prefrontal cortex,
duodenum, liver) were lysed in 10 volumes of RIPA lysis buffer
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Fig. 1. (a): A general outline of the generation of MB-
COMT deficient mice with site-directed knock-in
mutagenesis. Point mutations of ATGCTG Ò
GAGCTC of the MET1 site results in a change from
methionine (MET, M) to glutamic acid (Glu, E). NotI,
XbaI, SacI = restriction enzymes. Neo = neomycin
resistance element. MET1, MET2 = initiation codons
1 and 2.
(b): Sample agarose gel showing the bands for wild-
type (WT) as well as heterozygous (MB-COMT+/–)
and homozygous (MB-COMT-/-) MB-COMT
deficient mice. The PCR amplified fragments were
visualized with SYBR Green (Qiagen) staining under
UV light after electrophoresis in 1.7% agarose gel.
(c): Western blot analysis of COMT isoforms in wild-
type and MB-COMT deficient mice in the prefrontal
cortex, duodenum and liver. MB = MB-COMT, S =
S-COMT.
(d): Specific total COMT activities in the duodenum
(DUO), kidney (KID), liver (LIV), frontal cortex
(FC), hippocampus (HIP) and striatum (STR) of the
wild-type and MB-COMT deficient mice. Kidney
and liver values have been divided by ten to fit them
in the same graph with other tissues. *P < 0.05, ***P
< 0.001 versus corresponding male mice; n = 5 – 12,
Student's t-test after two-way ANOVA.
(20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 10% glycerol, 1%
NP-40, 2 mM EDTA) containing protease and phosphatase
inhibitors, homogenized manually, incubated for 20 min on ice
and centrifuged (18,000 g for 15 min at 4°C). The supernatants
were resolved by electrophoresis on a 4 – 20% precast gel (Mini
Protean TGX Gel, Biorad, Hercules, CA, USA). In some cases,
a prolonged running time was use for a better separation.
Proteins were transferred onto Trans-Blot Turbo Nitrocellulose
filter and transferred using the Trans-Blot Turbo Transfer system
(Biorad, Hercules, CA, USA). The membranes were blocked
with 0.1% (w/w) Tween-20/TBS containing 5% (w/w) non-fat
dried milk at room temperature for 1 hour. After blocking, the
membranes were incubated overnight with mouse anti-COMT
antibody (1:8000, BD Biosciences, Franklin Lakes, NJ, USA)
and mouse anti β-actin antibody (1:10000, clone AC-74, purified
immunoglobulins, 107K4791, Sigma-Aldrich Inc., MO, USA)
followed by incubation with goat anti-mouse secondary
antibody, HRP conjugated (1:2000, Thermo Fisher Scientific,
Waltham, MA, USA) for 1 hour at room temperature. The
membranes were incubated with ECL detection reagent (Thermo
Fisher Pierce, Rockford, IL, USA) for 5 min to visualize
proteins, and then visualized using C-Digit blot scanner (Li-
COR, Lincoln, NE, USA). Blots (Fig. 1C) and the relative
optical density values of protein bands were analyzed using
ImageJ (v.1.50i, NIH, Bethesda, MA) software. The reported
optical density values were calculated relative to actin band,
which was run parallel to each experiment.
Microdialysis
The method used has been described elsewhere in full detail
(40). Briefly, the mice were implanted with guide cannulas (AT-
4.7, AgnTho's AB, Lidingo, Sweden) under isoflurane anesthesia
and buprenorphine analgesia (0.05 mg kg–1 s.c. b.i.d. for 24
hours). The guide cannula was aimed at the mPFC (A/P = +1.8,
L/M = 0.5, D/V = –1.0) and striatum (A/P = +0.6, L/M = 1.8,
D/V = –2.2) according to the mouse brain atlas (41). After the
surgery, the animals were monitored for complications during
recovery. Animal was sacrificed if substantial weight loss or
signs of infection or illness were observed or if the guide cannula
fell off.
After a 5 - 7-day recovery period, a microdialysis probe (AT-
4.7.2, Agn Tho's AB, Lidingo, Sweden) perfused with artificial
cerebrospinal fluid (147 mM NaCl, 1.2 mM CaCl2, 2.7 mM KCl
and 1.0 mM MgCl2) was placed in the guide cannula at 7:30 AM.
After a 120-min stabilization period, collection of samples at 20-
min intervals commenced. After the collection of four baseline
samples, the animals were administered with carbidopa (30 mg
kg–1, i.p.) and L-DOPA (10 mg kg–1, i.p.). The drug doses were
chosen to match the ones used in our previous L-DOPA studies
(23, 42). After drug administration, sample collection continued
for five hours. Probe placements were verified afterwards from
brain sections mounted on glass slides. We aimed at having six
animals per each group because earlier experience with
microdialysis had indicated that this number would be large
enough to reveal significant differences in dopamine outflow. In
prefrontal cortex, there were 7 animals in male homozygous and
wild-type groups and female homozygous group, and 6 animals
in female wild-type group. In dorsal striatum, there were 6
animals in male and female homozygous groups, and 5 animals
in male and female wild-type groups.
The concentrations of dopamine, DOPAC and HVA in the
mPFC and dorsal striatal microdialysis samples were determined
by HPLC with electrochemical detection (40). Detection limits
for the system that was used for mPFC microdialysis samples
was 15 pM for dopamine, 0.4 nM for DOPAC and 0.6 nM for
HVA. Detection limits for the system that was used for dorsal
striatal microdialysis were 0.15 nM for dopamine, 5 nM for
DOPAC and 7 nM for HVA.
Behavioral tests
Owing to a limited number of animals, most of the
behavioral tests were performed in the same animals with at least
a one-day interval in an order from less stressful to more
demanding tasks. The order of testing and between-test intervals
are presented in Table 1.
1. Open field test for assessment of locomotor activity
Open field activity was determined between 9 AM and 2
PM. The open-field apparatus consisted of a four-sided 50 cm ×
50 cm × 50 cm (L × W × H) wooden box. The floor of the box
was divided into 16 squares. Each animal was tested for a 5-min
period. Animals (n = 7 in each group) were placed in the center
of the test cage and allowed to explore freely for 5 min. During
the test time, the number of squares passed were counted. After
each animal, the test apparatus was cleaned with a 10% ethanol
solution and water to remove any olfactory cues.
2. Object recognition test
On the second day of testing, the animal was placed in the
same cage as used in measuring locomotor activity with two
identical objects A and A' (clear plastic measuring cups).
Training took place by placing individual mice (n = 7 in each
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Test Between-test interval 
Open field test  
1 day 
Object recognition test  
1 day  
Hargrave’s plantar pain sensitivity test  
1 day  
Tail suspension test  
1 day 
Prepulse inhibition test  
7 days in individual cages 
Resident-intruder test (males only)  
Each male mouse (n = 7) went through all the 6 behavioral experiments and each female mouse (n = 7), went through all the 5
behavioral experiment, excluding test for aggressive behavior. One WT male and one WT female were excluded from the plantar pain
sensitivity test because it was not possible to keep their paw stable during the test.
Table 1. Test scheme of the behavioral test battery showing the order of tests and between-test intervals.
group) into the field for 5 min, into which the objects A and A'
were positioned in two adjacent corners, 10 cm from the walls.
The time spent exploring each object was registered. Two
hours later the animal was placed in the cage with objects A
and B. The object B (a red plastic pentagon) was novel and its
shape and color differed from the object A. Again, time spent
exploring the objects was registered. Difference in time spent
exploring the novel object B versus the familiar object A gave
an estimate of the function of short-term memory; mice with
intact short-term memory would concentrate on exploring the
novel object. Twenty-four hours later the animal was once
more placed in the cage, this time with objects A and C. The
object C (a green plastic pyramid) was novel and different
than the objects A and B. Time spent exploring these objects
gave an estimate of the function of long-term memory. The
objects B and C were different from each other because mice
with properly functioning long-term memory would
assumedly remember the object B from the previous testing
session.
The test is based on the fact that animals will not explore the
familiar objects as often as they explore a novel object. A
discrimination index for each object was expressed as a ratio of
the amount of time spent exploring the new object (B or C) [Tnew
/ (TA + Tnew)] * 100, where TA and Tnew are the times spent
exploring the familiar object A and the novel object,
respectively. Between trials, the objects were cleaned with 5%
ethanol solution. Exploration was defined as sniffing or touching
the object with the nose and/or forepaws. The time spent
exploring each object was videotaped and analyzed later.
3. Plantar test for pain sensitivity (Hargraves's method)
The plantar test was carried out using Ugo Basile SRL 7371
Plantar test apparatus (Varese, Italy). IR intensity was set to
60%. Animals (n = 6 – 7 in each group) were left to the chamber
for 20 min habituation period, after which the IR beam was
positioned under hind paw and withdrawal latency was
measured. For each animal, the withdrawal latency was
measured for both hind paws alternately three times. For
analysis, the mean withdrawal latency was calculated. Two
animals (one from each WT group) were excluded because they
did not calm down within one hour to allow the measurement to
be conducted, i.e. they did not stand still long enough that the
experimenter could have placed the IR beam under the paw.
4. Tail suspension test (TST)
TST is an analogue to the Porsolt forced swim test and is
based on the fact that mice suspended by the tail alternate
periods of struggle and immobility. Mice (n = 7 in each group)
were suspended by the tail, using adhesive tape, approximately
one cm from the base of the tail to a wooden beam. The total
duration of immobility during the 6-min test period was
measured. Immobility was defined as complete lack of
movements besides respiration.
5. Acoustic startle response and prepulse inhibition of acoustic
startle
Acoustic startle response and prepulse inhibition of acoustic
startle were assessed using two automated SRLab System
chambers (San Diego Instruments, San Diego, CA, USA). A
speaker located in the ceiling of the chamber provided
background noise (65 dB) and acoustic stimuli. A piezoelectric
sensor attached to the base transduced the startle response.
Baseline acoustic startle response was recorded at 68, 82, 90,
100, and 120 dB.
After a 5-min acclimation period, four successive trials of 40
ms noise bursts at 120 dB were presented (not included in the
analysis). Subjects (n = 7 in each group) were then exposed to
five different types of acoustic stimuli in a randomized order:
pulse alone (120 dB noise for 40 ms), no stimulus (background
noise only), and three separate prepulse pulse combinations,
with the prepulse (PPS) set at four sound levels of 68, 72, 76 and
80 dB for 20 ms followed by a 40 ms pulse at 120 dB. There
were 100 ms between the prepulse and the pulse. A total number
of 20 trials under each acoustic stimulus condition were
presented with an average 20-s variable ITIs randomly ranging
from 5 to 25 s. The startle amplitude for each trial was measured
for 65 ms starting from the onset of the startle stimulus. Percent
PPI of startle response was calculated as: PPI% = [1-(startle
response to PPS + pulse trial / startle response to pulse-alone
trial)] * 100.
6. Resident intruder test
Male mice (n = 7) were singly housed for a week. An
intruder from the opposite genotype was introduced to the home
cage of the resident. The number of threats, body sniffs and
bites, and latency to attack was measured. The cut-off time was
180 s.
Statistical analysis
All data are given as mean ± S.E.M. AUC values were
calculated employing the trapezoidal rule (calculated of time
points between 40 and 300 min for microdialysis data). The
microdialysis data was normalized to baseline (% of baseline)
before the calculation of AUCs.
For COMT activity data, microdialysis data as well as
behavioral data, two-way analysis of variance (ANOVA) with
sex and genotype as independent variables was used as the
statistical testing method. The statistical analysis of
microdialysis results was performed on the AUC values.
Repeated measures model was applied to acoustic startle
response and prepulse inhibition of acoustic startle as well as
COMT kinetic data. Since the initial two-way ANOVA for
repeated measures showed a significant sex effect, the sexes
were further analyzed separately with one-way repeated
measures ANOVAs. Student's t-test was used for the two-group
post hoc comparisons in all cases. Results from the resident-
intruder test were analyzed with Student's t-test only. Statistical
analysis was carried out using SPSS 22 software.
RESULTS
Generation and phenotype of MB-COMT deficient mice
The targeting vector used in the genetic engineering, WT
target allele, targeted allele construct after homologous
recombination as well as floxed allele after Cre recombination
in embryonic stem cells are presented in Fig. 1A. A sample
agarose gel blot of the PCR products of DNA extracted from ear
biopsies obtained from WT as well as heterozygous and
homozygous MB-COMT deficient mice is given in Fig. 1B.
Representative Western blots from prefrontal cortex, duodenum
and liver of male and female WT and homozygous MB-COMT
deficient mice (Fig. 1C) show that the latter express S-COMT
protein while no MB-COMT protein is present. When the
available S-COMT and actin (loading control) bands were
quantified, the S-COMT/actin ratios were similar in the tissues
obtained from WT and MB-COMT deficient mice. For
example, S-COMT/actin ratios were 1.20 ± 0.13 and 1.04 ± 0.11
831
in the liver and 0.64 ± 0.07 and 0.61 ± 0.06 in the striatum of
WT and MB-COMT deficient mice, respectively, indicating that
there was no evidence of compensatory upregulation of S-
COMT protein expression. Since the number of blots per each
tissue was limited, this should be considered as a preliminary
finding.
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DHBAc 
(M) 
Male 
wild type 
Male 
MB-COMT 
deficient 
Female 
wild type 
Female 
MB-COMT 
deficient 
COMT activity 
(pmol vanillic acid formed in minute per mg of protein) 
3  27.9 ± 5.6 29.8 ± 11  17.8 ± 1.8  16.7 ± 3.7 
30  146 ± 23  108 ± 14 86.0 ± 18 84.2 ± 10 
300 357 ±10  289 ± 31  244 ± 45  287 ± 25 
Vmax (min
–1
)  423 ± 26  351 ± 38  304 ± 59  390 ± 47 
Km (µM)    56 ± 12    65 ± 23    75 ± 47  108 ± 38 
   Mean S.E.M., n = 4–5. Two-way ANOVA indicated a sex difference across the concentration range [F2, 40 = 8.645, P < 0.01].
Table 2. Liver total COMT activities as a function of increasing concentrations of the substrate (DHBAc) and enzyme kinetic values
of WT and MB-COMT deficient mice.
Fig. 2. Medial prefrontal cortical microdialysis. Extracellular dopamine, DOPAC and HVA levels as well as AUC40–300 min values in
homozygous MB-COMT deficient (MB-COMT-/-) and wild-type (WT) mice of both sexes after L-DOPA (10 mg/kg, i.p.) and carbidopa
(30 mg/kg, i.p.) treatment. L-DOPA-carbidopa treatment was given at 0 min. Statistics of AUC analysis (Student's t test after two-way
ANOVA): #P < 0.05, male versus female, *P < 0.05, WT versus MB-COMT –/–. Data are given as percent from the baseline, mean ± S.E.M.
n = 6 – 7 per group.
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DHBAc 
(M) 
Male 
wild type 
Male 
MB-COMT 
deficient 
Female 
wild type 
Female 
MB-COMT 
deficient 
COMT activity  
(pmol vanillic acid formed in minute per mg of protein) 
30   8.9 ± 1.9   9.7 ± 2.6   8.6 ± 2.9   8.7 ± 2.3 
300 23.4 ± 2.3 22.9 ± 2.0 28.7 ± 4.9 20.7 ± 4.3 
   Mean ± S.E.M., n = 5 – 8.
Table 3. Hippocampal total COMT activities at two substrate (DHBAc) concentrations in WT and MB-COMT deficient mice.
Fig. 3. Dorsal striatal microdialysis.  Extracellular dopamine, DOPAC and HVA levels as well as AUC40–300 min valuesin homozygous
MB-COMT deficient (MB-COMT –/–) and wild-type (WT) mice of both sexes after L-DOPA (10 mg/kg, i.p.) and carbidopa (30 mg/kg,
i.p.) treatment. L-DOPA-carbidopa treatment was given at 0 min.  Statistics of AUC analysis (Student's t test after two-way ANOVA):
*P < 0.05, WT versus MB-COMT –/–. Data are given as percent from the baseline, mean ± S.E.M.; n = 5 – 6 per group.
COMT activity
The total COMT activities in the duodenum, kidney, liver,
hippocampus, prefrontal cortex and striatum of MB-COMT
mutant mice and their WT littermates are presented in Fig. 1D.
Overall, a lack of MB-COMT did not induce significant changes
in COMT activity. Female mice showed lower COMT activity in
the liver than male mice (two-way ANOVA: sex effect F1, 45 =
24.74; P < 0.001). Genotype and sex did not have an effect on
total COMT activity in the duodenum, kidney, hippocampus,
prefrontal cortex, and striatum.
No sex or genotype effects were detected in meta/para ratios
in any of the tissues studied. The values were always less than
15, which is typical for S-COMT activity (e.g. in the liver 6.8 ±
0.4 versus 6.9 ± 0.5 males and 6.2 ± 0.2 versus 6.1 ± 0.2 in
females in the WT and MB-COMT deficient mice, respectively.
In the PFC, the corresponding meta/para ratios were 8.5 ± 0.8
versus 8.3 ± 0.5 and 7.6 ± 0.6 versus 7.4 ± 0.5; mean ± S.E.M.,
n = 11). Therefore, sex and genotype did not have an effect on
the ratio between 3-O- and 4-O-methylation, despite the lack of
MB-COMT in MB-COMT mutant mice.
COMT enzyme kinetics
As expected, increased total COMT activity in the liver
(Table 2) and hippocampus (Table 3) homogenates was observed
with increasing concentrations of the substrate. There were no
significant differences in the kinetic values between genotypes
and sexes in the liver, or in COMT activity in the hippocampus.
However, there was a sex difference in liver COMT activity
across different substrate concentrations (two-way ANOVA for
repeated measures: F2, 40 = 8.645, P < 0.01). Meta/para ratios
were always less than 15, typical to S-COMT activity, even at
the lowest substrate levels (data not shown).
Microdialysis
In the mPFC, neither genotype nor sex per se had a
significant effect on extracellular dopamine, DOPAC or HVA
levels. However, the effect of genotype on dopamine and HVA
levels was sex-dependent (Two way ANOVA: dopamine: sex
genotype interaction, F1, 22 = 4.527, P < 0.05; HVA: sex ×
genotype interaction F1, 22 = 5.579, P < 0.05) (Fig. 2). In males,
the level of dopamine was lower in MB-COMT deficient animals
than WT animals, whereas female MB-COMT–/– mice showed
slightly higher dopamine levels than their WT counterparts. HVA
levels, on the other hand, were lower in female MB-COMT
deficient mice than WT animals. However, male MB-COMT–/–
mice showed a minimal increase in HVA as compared to their
WT littermates. Baseline levels uncorrected for probe recovery
were approximately 10 fmol per 35 µl for dopamine, 0.2 pmol per
35 µl for DOPAC and 0.5 pmol per 35 µl for HVA.
In the dorsal striatum, genotype had an effect on extracellular
dopamine levels (Two-way ANOVA: genotype effect F1, 18 =
8.130, P < 0.05) (Fig. 3). MB-COMT deficient mice showed
higher dopamine levels than their wild-type littermates. Neither
genotype nor sex had an effect on dorsal striatal DOPAC and HVA
levels. Baseline levels uncorrected for probe recovery were
approximately 100 fmol per 35 µl for dopamine, 3 pmol per 35 µl
for DOPAC and 1 pmol per 35 µl for HVA.
Behavior
1.Open field for assessment of locomotor activity
Assessment of locomotor activity did not show any differences
between WT and MB-COMT deficient animals (Fig. 4A).
2. Object recognition test
In object recognition test, short term memory of 2 h and
long-term memory of 24 h were assessed. There was a
significant difference between MB-COMT deficient and WT
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Fig. 4. (a): Number of squares crossed in the
open field in male and female MB-COMT
deficient mice (black columns) and their wild-
type (WT) littermates (open columns).
(b): Immobility time (s) of male and female
MB-COMT deficient mice (black columns)
and their wild-type (WT) littermates (open
columns) in the tail suspension test. The mice
were suspended by the tail using adhesive tape
and allowed to hang for 6 min. The immobility
time was recorded as a measure of
helplessness. A discrimination index (%) of
male and female MB-COMT deficient mice
(black columns) and their wild-type (WT)
littermates (open columns) in the object
recognition test.
(c): and (d): Training time was 5 min to
familiarize two identical objects. The
exploration time (5 min, to explore one
familiar and one new different object) was
tested after 2 hours (Fig. 2c) or 24 hours (Fig.
2d) delay. ***P < 0.001, Student's t-test after
two-way ANOVA.
(e): A plantar test for pain sensitivity was
performed using infrared beam exposure
(Hargrave's test) in male and female MB-
COMT deficient mice (black columns) and
their wild-type (WT) littermates (open
columns). After 20 min of habituation,
withdrawal latencies of the both hind paws
were measured alternating three times and the
mean values were calculated for each mouse.
n = 6 – 7, mean ± S.E.M.; *** P < 0.001
versus corresponding WT mice, Student's t-
test after two-way ANOVA. Two-way
ANOVA F-values are shown in figures.
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Fig. 5. Acoustic startle response (panels a and b) and prepulse inhibition of acoustic startle (panels c and d) were assessed using an
automated test chamber with a speaker in the ceiling providing background noise (65 dB) and acoustic stimuli as well as a piezoelectric
sensor in the base mediating the startle response.  The baseline startle response was tested at stimulus intensities of 68, 82, 90, 100, and
120 dB.  Before the prepulse inhibition test, four successive trials of 40 ms noise bursts at 120 dB were presented after a 5-min
acclimatization period (not included in the analysis).  Male and female MB-COMT deficient mice (black columns) and their wild-type
(WT) littermates (open columns) were then exposed to five different types of acoustic stimuli in a randomized order: pulse alone (120
dB noise for 40 ms), no stimulus (only background noise), and three separate prepulse pulse combinations, with prepulse set at four
sound levels of 68, 72, 76 and 80 dB for 20 ms followed by a 40 ms pulse at 120 dB.  There were 100 ms between the prepulse and the
pulse.  A total number of 20 trials under each acoustic stimulus condition were presented with an average 20-s variable inter-trial
intervals randomly ranging from 5 to 25 s.  The startle amplitude for each trial was measured for 65 ms starting from the onset of the
startle stimulus.  Mean ± S.E.M., n = 7. **P < 0.01, *** P < 0.001 versus corresponding WT mice, Student's t-test after repeated
measures one-way ANOVA.  Repeated measures one-way ANOVA results are shown in figures.  Note that repeated measures two-way
ANOVA did not show a sex difference in the startle amplitude data and, thus, separate one-way ANOVAs were not performed for male
and female animals.
mice in short-term memory in male as well as in female mice
where MB-COMT deficient animals from both sexes showed a
significantly lower novel object discrimination index (two-way
ANOVA: genotype effect F1, 28 = 76.622, P < 0.001) (Fig. 4C).
On the other hand, no differences were observed in long-term
memory between WT and MB-COMT deficient mice in the
novel object discrimination indexes (Fig. 4D).
3. Plantar test for pain sensitivity
Pain sensitivity was assessed using Hargrave's plantar test
method. Pain sensitivity was sex and genotype-dependent
(two-way ANOVA: sex effect F1, 22 = 4.478, P < 0.05; genotype
effect F1, 22 = 72.743, P < 0.001). Both male and female MB-
COMT deficient mice were more sensitive to pain than WT
animals as shown by shorter paw withdrawal latencies (Fig.
4E). The observed sex effect is caused by the shorter
withdrawal latencies found in both genotypes of female vs.
male mice.
4. Tail suspension test
The TST, which is mostly used to assess depressive-like
behavior, revealed a sex difference in the immobility time (two-
way ANOVA: sex effect F1, 28 = 13.504, P < 0.001). In addition,
the effect of MB-COMT deficiency on immobility time was
different between sexes (two-way ANOVA: genotype x sex
interaction F1, 28 = 8.764). Male, but not female, MB-COMT
deficient mice showed longer immobility time than
corresponding WT mice (Fig. 4B).
5. Acoustic startle response and prepulse inhibition of acoustic
startle
The acoustic startle response depended on the intensity of
sound and was different between sexes across a range of sound
intensities (68 – 120 dB) (two-way ANOVA: dB effect F4, 96 =
39.921, P < 0.001; dB × sex interaction F4, 96 = 4.325, P < 0.01)
(Fig. 5A and 5B).
Prepulse inhibition, which is used to determine the
sensorimotor gating function, was both sex and genotype-
dependent (two-way ANOVA: sex effect F1, 24 = 14.691, P <
0.001; genotype effect F1, 24 = 9.159, P < 0.01; sex genotype
interaction F1, 24 = 5.908, P < 0.05), and the level of inhibition
was intensity-dependent (two-way ANOVA: dB effect F3, 72 =
14.315, P < 0.001; dB sex interaction F3, 72 = 1,226, P > 0.05; dB
genotype interaction F3, 72 = 0.900, P > 0.05; dB sex genotype
interaction F3, 72 = 0.148, P > 0.05). Prepulse inhibition was
significantly reduced in MB-COMT deficient male mice
compared to WT animals throughout all prepulse intensities
(one-way ANOVA: males: genotype effect F1, 12 = 30.631, P <
0.001; dB effect F3, 36 = 3.635, P < 0.05; dB genotype
interaction F3, 36 = 0.255, P > 0.05) (Fig. 5C). Conversely, no
differences were seen between female WT and MB-COMT
deficient animals (one-way ANOVA: females: genotype effect
F1, 12 = 0.738, P > 0.05; dB effect F3, 36 = 12.039, P < 0.001; dB
genotype interaction F3, 36 = 0.801, P > 0.05) (Fig. 5D).
6. Resident-intruder test
Aggressive behavior was assessed with the resident-intruder
test in male WT and MB-COMT deficient mice. Analysis revealed
a shorter latency to attack in MB-COMT deficient mice compared
to WT mice (Student's t-test: t = 5.595, P < 0.001, n = 7), and these
animals also delivered more bites to the opposing mice (Student's
t-test: t = 2.954, P < 0.05, n = 7). In WT animals, on the other hand,
the number of body sniffs was higher (Student's t-test: t = 5.000, P
< 0.001, n = 7), indicating that WT animals were more social than
MB-COMT mice in whom aggressiveness was prominent (Fig. 6).
DISCUSSION
This novel mouse line specifically lacking MB-COMT
protein offers for the first time the possibility of revealing the
functional importance of MB-COMT. Both sexes of MB-COMT
deficient mice showed increased pain sensitivity and disturbed
short-term memory while their ambulatory activity remained
intact. However, the main finding of our behavioral study is that
exclusively MB-COMT deficient male mice exhibited behaviors
that can be considered as schizophrenia endophenotypes in
animal models such as aggressive behavior (34) and reduced
prepulse inhibition (36). Prolonged immobility in the tail
suspension test that was exclusively observed in male mice is
considered to be depression-like behavior. Depression can also
be associated with schizophrenia in humans (43). These
behavioral changes were present while the gross COMT activity
remained normal, even at low substrate concentrations. The
results of microdialysis experiments also show alterations in
dopamine metabolism in the dorsal striatum, a brain area that is
affected in schizophrenia (44): homozygous MB-COMT
deficient male mice showed higher dorsal striatal extracellular
dopamine levels than their WT littermates after L-DOPA-
carbidopa treatment. A summary of all major findings is shown
in Table 4.
Employing a behavioral test battery permits the use of
reduced number of mice per set of experiments. Nevertheless,
there is no doubt that many of the behavioral tests are stressful
and repeated stress may affect the results. Although both wild-
type and MB-COMT deficient mice were exposed to stress
similarly, it is possible that the latter are more sensitive to
stress than the former, which may have rendered them more
vulnerable to the behavioral manifestations that we observed.
However, we think that this limited behavioral test battery
demonstrates the main point: particularly the male MB-COMT
deficient mice show a distinct behavioral phenotype. Sex
differences in COMT-related neurochemistry and behaviors
have been regularly reported (2, 37). We are aware of the
importance of sex hormones on COMT biology, and our
previous investigations have shown that their effects are
complex and tissue dependent (45). It was not practically
feasible to synchronize the estrous cycle in the present sets of
experiments, which may have increased variability in the
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Fig. 6. Resident intruder test in male MB-
COMT deficient mice (black columns)
and their wild-type (WT) littermates
reflecting aggressive behavior. The mice
were housed individually for one week.
An intruder of the opposite genotype was
presented into the home cage of the
resident for a maximum of 180 s and the
following parameters were counted:
number of body sniffs, number of threats,
latency to attacks (min), and number of
bites. Females did not show any
aggressive behavior. n = 7, mean ±
S.E.M. * P < 0.05, *** P < 0.001 versus
corresponding WT mice, Student's t-test.
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Effect of MB-COMT deficience 
 Males Females Difference between females and males
Total COMT activity 
Liver 
Brain tissue 
± 
±
± 
±
Lower COMT activity in females 
 ± 
Extracellular dopamine 
mPFC 
Striatum 
± 
↑↑
± 
(↑ NS) 
± 
±
Open field activity ± ±   ±
Tail suspension
(depression 
endophenotype in mice) 
↑↑ ±
No depression endophenotype in 
females 
Object recognition 
2 hours 
24 hours 
↓↓
±
↓↓
±
± 
±
Pain sensitization ↑↑ ↑↑ ±
Startle amplitude (↑ NS)  ± ±
Prepulse inhibition ↓↓ ± No effect in females 
Aggressive behavior ↑↑ Not measured Aggression tests are not used with 
female mice. 
Key: ±, no significant effect; ÓÓ significant increase; ÔÔ , a significant decrease. Additionally, we have shown two tendencies
towards increase (ÓÓ NS) although they are not statistically significant.
Table 4. A summary of biochemical and behavioral findings induced by the lack of MB-COMT. Sex difference is indicated when applicable.
results of behavioral and microdialysis studies in female mice.
Pain sensitization, 2-hour object recognition and general
motility data were, however, similar in both sexes. It is
unlikely that behavioral effects that were prominent in male
mice would have been completely absent in females simply
because of the estrus cycle induced variation. Therefore, we
present the behavioral and microdialysis data obtained from
female mice as well. However, we point out that these results
should be judged with caution.
Unaltered total COMT activity in the mice lacking MB-
COMT could be explained by a significant differences of
enzyme kinetic properties of the two COMT isoforms. As
mentioned in Introduction (1, 9-13), Km value of MB-COMT is
less than one hundredth of the corresponding value of S-COMT.
In addition, the meta/para ratio suggests dominance of O-
methylation by S-COMT even in WT mice (less than 15,
typically around 8 in our studies) and this ratio did not differ
between the WT and MB-COMT deficient mice in any tissue
studied. All in all, these findings suggest that S-COMT is the
dominating enzyme of overall COMT activity in the body.
Compared to S-COMT, the enzymatic capacity of MB-COMT is
limited and even the complete lack of it is not detectable in the
gross COMT activity or in the meta/para ratios. It is well known
that COMT activity is easily down regulated, e.g. by estrogens,
but we are not aware of any convincing evidence of up
regulation of either COMT isoforms (2). Even in the present
study, our preliminary findings do not support an increase in the
amount of S-COMT protein in the MB-COMT deficient mice. It
is interesting to note that in the S-COMT deficient mice (23),
MB-COMT was able to maintain about 70% of the total COMT
activity, suggesting that under extreme conditions it can
compensate for missing S-COMT protein. MB-COMT certainly
has a function under normal conditions as well, and our
behavioral results in MB-COMT deficient mice give hints of its
functional role in some brain areas.
We carried out microdialysis experiments in the mPFC and
dorsal striatum to find out how MB-COMT deficiency affects
carbidopa-L-DOPA induced dopamine efflux (Figs 2 and 3). The
mPFC was one of our areas of choice because of extremely low
dopamine transporter levels (46-48) and, hence, accentuated
importance of COMT-mediated O-methylation in dopamine
metabolism in this brain region (40, 49). However, in the mPFC,
MB-COMT deficiency did not significantly alter dopamine
levels induced by L-DOPA-carbidopa treatment. This may be
due to the fact that MB-COMT deficient mice showed unaltered
COMT activity also in the mPFC. However, in the dorsal
striatum, the extracellular levels of dopamine were higher in
MB-COMT deficient mice than in WT animals. This was
unexpected since neither full Comt knock-out mice nor S-
COMT deficient mice showed an increase in striatal dopamine in
response to carbidopa-L-DOPA treatment (23, 42). Full Comt
knock-outs may have developed compensatory mechanisms that
prevent the accumulation of these catechols. Such compensation
was apparently not needed in the selective absence of MB-
COMT since total COMT activity was not decreased. These
findings may be more understandable in the light of a close
interaction of the mPFC and striatum described by Simpson et
al. (44, 50). They found that local overexpression of COMT in
the PFC caused enhanced dopamine release in the striatum. In
the present study, COMT activity in the mPFC was intact while
L-DOPA-induced striatal dopamine release was potentiated in
MB-COMT deficient mice. Enhanced striatal dopaminergic
activity is one of the hallmark neurochemical manifestations of
schizophrenia (44).
MB-COMT deficient mice behaved and moved normally
under resting conditions. In this sense, they resembled Comt
knock-out mice, both homozygous and heterozygous, whose
diurnal activity and general behavior are mostly undisturbed (38).
Papaleo et al. (51) showed that altered COMT activity, either
increased or decreased, did not affect the general health or
physical abilities of mice. Recent studies by Risbrough et al. (52)
produced similar findings in humanized mice carrying Val/Met
alleles of the human COMT Val158Met polymorphism. Met/Met
females expressing low COMT activity were rearing more than
Val/Val females (52). Conversely, Babovic et al. (53) found in
elaborate ethogram observations that, during the initial 60 minutes
of testing, heterozygous Comt knock-out mice of both sexes
exhibited decreased rearing and increased sifting and chewing
while the behavior of homozygous Comt knock-out animals did
not differ from the WT mice. S-COMT deficient mice generally
behaved like WT mice except that females travelled shorter
distances in the elevated plus maze and open field (39). Mice over-
expressing of COMT protein showed marginally decreased (54) or
no effect (50) on locomotor activity.
One of the most robust findings in COMT related behaviors
is the alteration of pain sensitivity. We found increased
sensitivity to thermal pain in both sexes of MB-COMT deficient
mice in the plantar withdrawal test, which is in line with the
shortened tail-flick time observed in the Comt knock-out mice
(55). These results are in contrast to our findings in S-COMT
deficient male mice in which baseline latency in the tail-flick test
was prolonged (39). Collectively, these findings point to a
critical role of MB-COMT isoform in nociception and suggest
that low COMT activity may sensitize to acute pain. In addition,
several studies have shown that administration of selective
COMT inhibitors increases thermal, mechanic and inflammatory
pain in rodents (55, 56). Findings in humans concerning the link
between the Val158Met polymorphism and pain conditions
partially and moderately support the results from animal studies.
As shown by our meta-analyses (57), the low COMT activity
allelic variant Met158 was associated with chronic pain, though
only in patients with fibromyalgia or certain related widespread
pain conditions. Although the Met158 allele in humans and
COMT inhibitors in acute rodent pain models are
pronociceptive, repeated administration of nitecapone produces
an antiallodynic effect in neuropathic pain models (58, 59). The
complex interplay between enhanced adrenergic and
dopaminergic activity in different parts of the nociceptive
system probably explains the complex effects of low COMT
activity on pain sensations; this enigma has been described and
discussed in recent reviews (57, 60).
Prolonged immobility in the tail suspension test or forced
swimming test is considered to reflect hopelessness and
depression. In our study, immobility time was significantly
prolonged only in male MB-COMT deficient mice. In
homozygous Comt knock-out mice, we did not see any change in
the forced swimming time in male mice (39), and over-
expression of the 22q11.2 segment, causing a doubling of COMT
activity, did not alter the immobility time in the tail suspension
test (54). Results with selective COMT inhibitors in combination
with L-DOPA (61) have shown shortened immobility times.
Similarly, in a long-term tolcapone study, anhedonia was
effectively reversed (62). Tolcapone has shown antidepressant
properties even in human patients (63). Numerous studies have
explored the link between the Val158Met polymorphism and
depression (64, 65) as well as the correlation between the
Val158Met polymorphism and the efficacy of various
antidepressants (65) with highly variable results. Collectively, the
existing evidence from human studies implies that Met carriers
with relatively low COMT activity may be more vulnerable to
depression than individuals with the double Val allele, and this
predisposition may be due to an altered stress response.
Regarding cognition-related behaviors, both male and
female MB-COMT deficient mice had a lower object
recognition index (34% and 38% decrease in males and females,
respectively) than their WT littermates at 2 h after training. At 24
h, the effect was no longer present, suggesting that short-term
memory was compromised in the MB-COMT deficient animals
while long-term memory was intact. Babovic et al. (66)
observed a similar deterioration in a novel object recognition
test, but only in heterozygous Comt knock-out mice; this was
observed more robustly in males than females. Homozygous
Comt knock-out mice performed normally in the test. We have
also studied the effect of selective COMT inhibitors on single-
trial passive-avoidance retention in male rats (67). Contrary to
the present findings, fairly high doses of entacapone and
tolcapone improved several phases of learning and memory that
were impaired either by scopolamine or brain lesions. Similarly,
tolcapone treatment modestly improves the accuracy of working
memory in abstinent smokers (68). However, tolcapone studies
have generally yielded less convincing results (cited in 68).
Effect of the human Val/Met polymorphism on various cognitive
functions has been amply studied, but the results have not been
quite uniform (69). These actions seem to be present only in
males and postmenopausal females, both healthy and
schizophrenic, suggesting that hormonal environment is a
reasonable cause for variability (70). Supporting our results from
the rat studies (67), it appears that individuals with a low COMT
activity, carrying the Met allele, perform best in tests of
declarative memory (71), whereas Val-allele carriers perform
worse in tests of recognition memory (28). High (or normal) and
low COMT activity mouse models mimicking the human
Val158Met polymorphism have been created by introducing a
Val allele (51) or either a Val or Met allele (52) into the mouse
genome. Moreover, to decrease or increase COMT activity,
respectively, the chromosome segment 22q11 has been
hemizygously deleted (72) or the human chromosome segment
22q11.2 has been overexpressed (54) in mice. Simpson et al.
(50) overexpressed COMT selectively in forebrain neurons
using a double transgenic technique. Most but not all of these
studies have found such alterations in cognition-related
parameters that favor the view of high COMT activity being
harmful and low activity being beneficial for working memory.
As a whole, based on both mouse and human studies, altered
COMT activity and the subsequent change in dopaminergic tone
in COMT-dependent brain areas, such as the prefrontal cortex,
are associated with cognitive functions. Based on our results,
MB-COMT seems to be the critical COMT isoform for cognitive
functioning. A shortage of COMT produces significantly
increased thickness and neuronal density in the brain cortex but
only in males, giving an anatomical background for sex
differences that have been observed in several behaviors (73).
The Val158Met polymorphism is associated with
schizophrenia as well as aggression, impulsive behavior and
working memory deficits (31-33). However, based on large meta-
analyses, the COMT polymorphism is not directly associated with
schizophrenia in general (74, 75) but rather with the aggressive
form of schizophrenia (34, 76, 77). Our present results showing
highly increased aggressiveness and reduced prepulse inhibition
in male mice deficient of MB-COMT fit very well with these
human findings. Increased aggressive behavior has been reported
also in heterozygous, but not in homozygous, Comt knock-out
mice (37). However, increased impulsiveness was reported even
in homozygous Comt knock-out mice by Papaleo et al. (78), who
also observed that the acute startle response was enhanced in these
mice while prepulse inhibition remained normal. In MB-COMT
deficient mice, startle amplitude was not altered in either sex but
prepulse inhibition was reduced in male mice. Increased COMT
activity induced by different genetic manipulations does generally
not affect prepulse inhibition (50, 54), but male Val/Val mice with
high COMT activity had lower prepulse inhibition than Met/Met
males with low COMT activity, while an opposite correlation was
observed in female mice. Interestingly enough, in the resident
intruder test in mice, intruders had a significant down-regulation
of COMT expression in the hippocampus while residents had
higher COMT expression (79).
Studies in various human populations have shown that
polymorphisms found in COMT promoter regions are associated
with risk of schizophrenia. Nicodemus et al. (80) showed in
Caucasians that a haplotype of three COMT SNPs [rs4680
(Val158Met), rs2097603 (located in promoter P2), and
rs165599] is associated with risk of schizophrenia. Honea and
coworkers (81) found an association between a haplotype of
rs4680 and rs2097603 and grey matter volume in hippocampus
and dorsolateral prefrontal cortex in mentally and neurologically
healthy Caucasians, highlighting the impact of these SNPs on
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the structure of brain areas relevant for schizophrenia. Wright et
al. (82) in turn reported that in South African Xhora population
two P2 region SNPs, rs2020917 and rs737865, were associated
with risk of schizophrenia as well as increased reporter gene
expression. Furthermore, a haplotype comprising the P2 region
was found to be associated with the severity of negative
symptoms of schizophrenia. Most recently, a copy number
variation polymorphism in promoter P1 was suggested to be
associated with schizophrenia in a Japanese population (83).
Although a mutation of the initiation codon as such is
specific, we want to point out that the methylation status of the
CpG (cytosine-phosphate-guanosine) islands in the COMT
promoter areas seems to be associated with the COMT Val/Met
polymorphism (84, 85). DNA methylation can affect gene
transcription via interactions with chromatin proteins and
binding of enhancers or transcription factors (85). Altered DNA
methylation, either inherited or dictated by epigenetic factors,
has been suggested to be associated with schizophrenia (86),
drug abuse (87), other mental disorders (88, 89) and even
cancers (90). This effects can be synergistic or independent of
known genetic polymorphism. Low DNA methylation induces
increased expression of both isoforms of COMT protein (86).
Generally, the behavior of MB-COMT deficient mice
resembles to some extent that of heterozygous Comt knock-out
mice, both of which have enough COMT activity to minimize the
need to develop compensatory mechanisms. Notably, the
behavioral findings in both types of mice are much more versatile
and robust than those reported in homozygous Comt knock-out
mice (37, 39, 53, 55, 91-93) or selectively S-COMT deficient
mice (39). It remains open why selective lack of MB-COMT has
multiple behavioral consequences. Our microdialysis findings
indicate that these mice have increased striatal but decreased
prefrontal cortical extracellular fluid dopamine levels pointing to
the site-specific alterations in dopamine handling that are
characteristic to cognitive symptoms in schizophrenia (44).
There are also other factors that regulate dopaminergic tone
in the brain. One is the intensity of the retrograde transport of
dopamine from the cavernous sinus to dopamine-rich brain areas,
adding a peripheral component to dopamine balance that is
critical, among others, for schizophrenia, Parkinson's disease and
dementia (94). Another, commonly missed regulatory link may
be the kynurenic pathway of L-tryptophan metabolism. This
pathway may be seriously down-regulated by epigenetic factors
like poor diet, lack of group B vitamins or excessive exercise
indirectly modulating glutamatergic and dopaminergic functions
in the brain. Also, altering levels of 5-hydroxytryptamine,
interfering with actions of dopamine, and toxic metabolites of L-
tryptophan may play a role in psychiatric disorders (95).
In conclusion, the main finding of our study is that exclusively
MB-COMT deficient male mice exhibit schizophrenia-associated
behavioral abnormalities such as aggressive behavior and reduced
prepulse inhibition. Both male and female mice exhibited normal
motor activity, but they were sensitized to acute pain and showed
impaired short-term memory, suggesting that the behavioral
phenotype was limited neither to schizophrenia-related behavioral
endophenotypes nor sex (Table 4). Our findings indicate that, of
the two COMT isoforms, MB-COMT is critical for normal
behavior and its function in COMT-dependent brain areas cannot
be entirely substituted by S-COMT. This is in contrast with S-
COMT, the lack of which can be effectively compensated for by
MB-COMT even in the peripheral tissues, as shown by our earlier
studies on S-COMT deficient mice.
Abbreviations: ANOVA, analysis of variance; COMT,
catechol-O-methyltransferase; DHBAc, dihydroxybenzoic acid;
L-DOPA, L-3,4-dihydroxyphenylalanine; MB-COMT,
membrane-bound catechol-O-methyltransferase; PPI, prepulse
inhibition; SAM, S-adenosyl-L-methionine; S-COMT, soluble
catechol-O-methyltransferase; S.E.M., standard error of mean;
TST, tail suspension test; WT, wild-type
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